4.7 Article

Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy

期刊

ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 54, 期 2, 页码 176-182

出版社

WILEY
DOI: 10.1111/apt.16408

关键词

-

资金

  1. NIDDK Intramural Research Program

向作者/读者索取更多资源

Extended course of peginterferon therapy resulted in sustained clearance of HDV RNA and favorable clinical outcomes in more than half of patients, with about a third clearing HBsAg. Responders had significantly lower rates of death or liver-related events compared to non-responders.
Background Hepatitis delta virus (HDV) infection is the most aggressive form of chronic viral hepatitis. Response rates to therapy with 1- to 2-year courses of pegylated interferon alpha (peginterferon) treatment are suboptimal. Aims To evaluate the long-term outcomes of patients with chronic hepatitis D after an extended course of peginterferon. Methods Patients were followed after completion of trial NCT00023322 and classified based on virological response defined as loss of detectable serum HDV RNA at last follow-up. During extended follow-up, survival and liver-related events were recorded. Results All 12 patients who received more than 6 months of peginterferon in the original study were included in this analysis. The cohort was mostly white (83%) and male (92%) and ranged in age from 18 to 58 years (mean = 42.6). Most patients had advanced but compensated liver disease at baseline, a median HBV DNA level of 536 IU per mL and median HDV RNA level of 6.86 log(10) genome equivalents per mL. The treatment duration averaged 6.1 years (range 0.8-14.3) with a total follow-up of 8.8 years (range 1.7-17.6). At last follow-up, seven (58%) patients had durable undetectable HDV RNA in serum, and four (33%) cleared HBsAg. Overall, one of seven (14%) responders died or had a liver-related event vs four of five (80%) non-responders. Conclusions With further follow-up, an extended course of peginterferon therapy was found to result in sustained clearance of HDV RNA and favourable clinical outcomes in more than half of patients and loss of HBsAg in a third.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据